Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Cardiology

How Often Should I Get a Cardiac MRI for Fabry Disease?

At a Glance

Patients with asymptomatic late-onset Fabry disease should get a baseline Cardiac MRI at diagnosis, followed by routine scans every 1 to 2 years. This proactive screening is crucial to detect silent fat buildup and heart scarring early, allowing for treatments that protect long-term heart function.

In this answer

4 sections

01

Why “Silent” Damage Happens

02

Why a Cardiac MRI is the Gold Standard

03

What to Expect During the Scan

04

The Goal: Catching Damage Early

If you have late-onset Fabry disease but no symptoms, guidelines generally recommend you get a baseline Cardiac MRI at the time of diagnosis, followed by a routine Cardiac MRI every 1 to 2 years [1][2]. This proactive screening is crucial because the late-onset cardiac variant of Fabry disease can cause “silent” damage to your heart muscle long before you feel any symptoms like shortness of breath, fatigue, or irregular heartbeats [3][4].

Why “Silent” Damage Happens

In the late-onset variant (often associated with specific genetic mutations like the p.N215S variant), the disease primarily targets the heart [5]. A specific type of fat called globotriaosylceramide (GL-3) slowly builds up in your heart cells. Over time, this buildup causes two major issues that a Cardiac MRI looks for:

  • Left Ventricular Hypertrophy (LVH): The heart muscle walls, particularly in the left lower chamber, become abnormally thick and stiff [4].
  • Myocardial Fibrosis: This is permanent scarring in the heart muscle [6].

The danger is that structural changes often begin occurring quietly [4]. By the time you start noticing symptoms, the structural changes to your heart might already be advanced [7].

Why a Cardiac MRI is the Gold Standard

While echocardiograms (heart ultrasounds) and ECGs (electrocardiograms) are extremely helpful and frequently used alongside MRIs, a Cardiac MRI (CMR) is considered the most accurate imaging test for monitoring Fabry disease [8][9]. It provides incredibly detailed images and uses specific techniques to assess the health of your heart tissue:

  • Late Gadolinium Enhancement (LGE): This technique uses a contrast dye (gadolinium) to highlight areas of myocardial fibrosis (scarring) [10][11]. Detecting scarring is one of the most important ways your care team determines your risk for future heart problems [12]. Note: Because Fabry disease can also affect the kidneys, and healthy kidneys are required to safely process the contrast dye, your doctor should check your kidney function with a simple blood test before approving the use of contrast.
  • T1 Mapping: This is a specialized MRI setting that detects the specific type of fat buildup (GL-3) in the heart muscle. It can often spot abnormalities before any physical thickening (LVH) or scarring has occurred [13][11].

What to Expect During the Scan

Getting an MRI can be intimidating, especially if you feel perfectly healthy. Knowing what to expect can help you prepare:

  • Time: A Cardiac MRI is a detailed test and typically takes 45 to 60 minutes.
  • Environment: The MRI machine is a long, narrow tube, which can feel claustrophobic. It is also very loud during the scan, so you will usually be given earplugs or headphones to listen to music.
  • Breath-holding: You will be asked to hold your breath multiple times for 10 to 15 seconds so the machine can capture clear pictures of your beating heart without motion blur.
  • Managing anxiety: If you are claustrophobic or highly anxious, ask your doctor in advance if a mild sedative is appropriate for you.

The Goal: Catching Damage Early

The main reason to undergo regular Cardiac MRIs every 1 to 2 years is to catch the very earliest signs of heart involvement [1][14].

If your MRI shows that the disease is starting to affect your heart, your doctor may recommend starting treatments like Enzyme Replacement Therapy (ERT) or chaperone therapy (an oral medication that helps your body’s own enzymes work correctly) [15][16]. Initiating treatment early, before irreversible scarring (fibrosis) has set in, is the most effective way to protect your heart function and improve your long-term health [17][18].

Common questions in this guide

How often should I get a Cardiac MRI if I have no symptoms of Fabry disease?
If you have late-onset Fabry disease without symptoms, guidelines recommend getting a baseline Cardiac MRI at diagnosis, followed by a routine scan every 1 to 2 years. This helps monitor for silent changes in your heart before you feel sick.
Why is a Cardiac MRI better than an echocardiogram for Fabry disease?
While echocardiograms are useful, a Cardiac MRI provides highly detailed images of your heart tissue. Using specialized techniques like T1 mapping and late gadolinium enhancement, an MRI can detect fat buildup and scarring much earlier than other routine tests.
Do I need a kidney test before my Cardiac MRI?
Yes, your doctor should check your kidney function with a blood test before the scan. This ensures your kidneys are healthy enough to safely process the gadolinium contrast dye used to highlight heart scarring.
How long does a Cardiac MRI take and what should I expect?
The scan typically takes 45 to 60 minutes. You will be asked to hold your breath for short periods to prevent motion blur, and you can request a mild anxiety medication from your doctor in advance if you experience claustrophobia.
What happens if my Cardiac MRI shows heart damage from Fabry disease?
If your scan detects early signs of heart involvement, your doctor may recommend starting treatments like Enzyme Replacement Therapy (ERT) or chaperone therapy. Catching and treating the disease before irreversible scarring occurs is the best way to protect your heart.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my specific genetic variant, what timeline do you recommend for my baseline and follow-up Cardiac MRIs?
  2. 2.What is the CPT billing code for the MRI so I can check my coverage and out-of-pocket costs with my insurance beforehand?
  3. 3.Will you be doing a blood test to check my kidney function before administering the gadolinium contrast dye?
  4. 4.Can you prescribe a mild anti-anxiety medication to help me get through the 45-60 minute MRI scan if I experience claustrophobia?
  5. 5.How will we coordinate my MRI results with my routine echocardiogram and ECG checkups to get a complete picture of my heart health?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can Female Carriers of Fabry Disease Have Severe Symptoms?How Is Enzyme Replacement Therapy Administered for Fabry?How Is Fabry Disease Inherited From a Father?How Is Fabry Disease Inherited From a Mother?How Do You Manage Heat Intolerance in Fabry Disease?How to Transition a Child With Fabry to Adult CareHow to Treat Fabry Disease Nerve Pain in Hands & FeetCan Your Body Stop Responding to Fabry Disease ERT?What Are the Common Misdiagnoses for Fabry Disease?What Does an Amenable Mutation Mean in Fabry Disease?Fabry Disease Prognosis: What Is the Life Expectancy?What is the Lyso-Gb3 Test for Fabry Disease?What Specialists Treat Fabry Disease? Care Team GuideWhy Do Women Need Genetic Testing for Fabry Disease?

References

References (18)
  1. 1

    Cardiac Manifestations in Fabry Disease: A Case Report on Two Siblings.

    Kovačić S, Nadarević T, Žauhar P, et al.

    Diagnostics (Basel, Switzerland) 2025; (15(3)) doi:10.3390/diagnostics15030340.

    PMID: 39941270
  2. 2

    Arrhythmogenesis in Fabry Disease.

    Roy A, Cumberland MJ, O'Shea C, et al.

    Current cardiology reports 2024; (26(6)):545-560 doi:10.1007/s11886-024-02053-2.

    PMID: 38607539
  3. 3

    Late-onset fabry disease presenting with unexplained renal failure, left ventricular hypertrophy, and recurrent syncope: a case report.

    Ying Q, Yang X, Zhao N, et al.

    Orphanet journal of rare diseases 2025; (20(1)):271 doi:10.1186/s13023-025-03791-4.

    PMID: 40462218
  4. 4

    New insights for early assessment of cardiac involvement in Anderson-Fabry disease.

    Cuocolo A, Nappi C, Gaudieri V, et al.

    Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 2021; (28(6)):2500-2502 doi:10.1007/s12350-019-01635-w.

    PMID: 30725338
  5. 5

    Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study.

    Germain DP, Brand E, Burlina A, et al.

    Molecular genetics & genomic medicine 2018; (6(4)):492-503 doi:10.1002/mgg3.389.

    PMID: 29649853
  6. 6

    Cardiac Fabry Disease With Late Gadolinium Enhancement Is a Chronic Inflammatory Cardiomyopathy.

    Nordin S, Kozor R, Bulluck H, et al.

    Journal of the American College of Cardiology 2016; (68(15)):1707-1708 doi:10.1016/j.jacc.2016.07.741.

    PMID: 27712787
  7. 7

    Cardiac Imaging in Anderson-Fabry Disease: Past, Present and Future.

    Esposito R, Santoro C, Mandoli GE, et al.

    Journal of clinical medicine 2021; (10(9)) doi:10.3390/jcm10091994.

    PMID: 34066467
  8. 8

    Comparison of Cardiac Magnetic Resonance Imaging and Echocardiography in Assessment of Left Ventricular Hypertrophy in Fabry Disease.

    Hazari H, Belenkie I, Kryski A, et al.

    The Canadian journal of cardiology 2018; (34(8)):1041-1047 doi:10.1016/j.cjca.2018.03.011.

    PMID: 29935990
  9. 9

    Left Ventricular Mass and Wall Thickness Measurements Using Echocardiography and Cardiac MRI in Patients with Fabry Disease: Clinical Significance of Discrepant Findings.

    O'Brien C, Britton I, Karur GR, et al.

    Radiology. Cardiothoracic imaging 2020; (2(3)):e190149 doi:10.1148/ryct.2020190149.

    PMID: 33778580
  10. 10

    Left Ventricular Hypertrophy and Late Gadolinium Enhancement at Cardiac MRI Are Associated with Adverse Cardiac Events in Fabry Disease.

    Hanneman K, Karur GR, Wasim S, et al.

    Radiology 2020; (294(1)):42-49 doi:10.1148/radiol.2019191385.

    PMID: 31660802
  11. 11

    Differentiation between Fabry disease and hypertrophic cardiomyopathy with cardiac T1 mapping.

    Deborde E, Dubourg B, Bejar S, et al.

    Diagnostic and interventional imaging 2020; (101(2)):59-67 doi:10.1016/j.diii.2019.08.006.

    PMID: 31519470
  12. 12

    Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis, Prognosis, and Treatment of Infiltrative Cardiomyopathies.

    Ranganath PG, Tower-Rader A

    Current cardiology reports 2021; (23(7)):87 doi:10.1007/s11886-021-01518-y.

    PMID: 34081227
  13. 13

    Multimodality Imaging Assessment of Fabry Disease.

    Tower-Rader A, Jaber WA

    Circulation. Cardiovascular imaging 2019; (12(11)):e009013 doi:10.1161/CIRCIMAGING.119.009013.

    PMID: 31718277
  14. 14

    Fabry disease cardiomyopathy: A practical guide for cardiologists.

    Al Saleh T, Qadeer YK, Yue B, et al.

    Current problems in cardiology 2026; (51(4)):103266 doi:10.1016/j.cpcardiol.2026.103266.

    PMID: 41544783
  15. 15

    Fabry-specific treatment in Australia: time to align eligibility criteria with international best practices.

    Nicholls K, Denaro C, Tchan M, et al.

    Internal medicine journal 2024; (54(6)):882-890 doi:10.1111/imj.16327.

    PMID: 38212950
  16. 16

    Later Onset Fabry Disease, Cardiac Damage Progress in Silence: Experience With a Highly Prevalent Mutation.

    Hsu TR, Hung SC, Chang FP, et al.

    Journal of the American College of Cardiology 2016; (68(23)):2554-2563 doi:10.1016/j.jacc.2016.09.943.

    PMID: 27931613
  17. 17

    The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts.

    Germain DP, Elliott PM, Falissard B, et al.

    Molecular genetics and metabolism reports 2019; (19()):100454 doi:10.1016/j.ymgmr.2019.100454.

    PMID: 30775256
  18. 18

    Treatment of Anderson-Fabry Disease.

    Simonetta I, Tuttolomondo A, Daidone M, et al.

    Current pharmaceutical design 2020; (26(40)):5089-5099 doi:10.2174/1381612826666200317142412.

    PMID: 32183665

This page is for informational purposes only and does not replace professional medical advice. Always consult your cardiologist or medical geneticist regarding your specific MRI schedule and Fabry disease monitoring.

Get notified when new evidence is published on Fabry disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.